| Sumario: | Significance & Background: Amyloid light-chain (AL) amyloidosis is a rare disorder caused by the buildup of abnormal light chains in various organs, including the heart and kidneys. When working with this patient population, it was noted that interdisciplinary collaboration with cardiology and nephrology was necessary for improving patient outcomes. So, the plasma cell disorder clinic created a monthly multi- disciplinary meeting to discuss the complex disease that is AL amyloidosis and provide multidisciplinary care on real patients, while providing education to reduce knowledge gaps and increase collaboration. This meeting occurs monthly and includes 20-30 minutes of AL amyloidosis-specific content followed by 30 minutes of patient case discussions. Purpose: While AL amyloidosis treatment is primarily managed by the hematology clinic, these patients require close follow-up with our colleagues in nephrology, cardiology, neurology, palliative care and bone marrow transplant. Communication across these specialties was identified as a barrier. This meeting was started to strengthen communication and shared decision-making to improve patient care. Interventions: This multidisciplinary meeting brings together MDs, APRNs, pharmacists and nurses across each group. Each meeting, a new presenter shares a lecture related to AL amyloidosis followed by questions for the presenter. After the education portion, providers from each group have the platform to discuss patient cases presented in PowerPoint format with questions for their colleagues. Working with the Education Department, this meeting offers free continuing education for the healthcare members who attend. Members are educated on the importance of adhering to HIPAA/ privacy requirements. Results: Starting in March of 2024, 18 total meetings have been held, averaging 4 patient case discussions per meeting and between 2030 attendees. The feedback has been overwhelmingly positive, with participants describing it as a wonderful opportunity for learning and interdisciplinary collaboration. Using qualitative feedback offered by the CE platform, improvements have been made. Discussion: The goal is to continue offering this opportunity for MDs, APRNs, pharmacists and nurses to deepen their understanding of AL amyloidosis. In the future, our target is to offer this meeting to community sites to continue to facilitate education and collaborate to improve patient care. Truly, we are better together in tackling AL amyloidosis.
|
|---|